1
|
Pina PSS, Jang Y, Emerick C, Scarini JF, Sousa SCOM, Squarize CH, Castilho RM. Novel Epigenetic Modifiers of Histones Presenting Potent Inhibitory Effects on Adenoid Cystic Carcinoma Stemness and Invasive Properties. Int J Mol Sci 2024; 25:1646. [PMID: 38338924 PMCID: PMC10855771 DOI: 10.3390/ijms25031646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2023] [Revised: 01/24/2024] [Accepted: 01/25/2024] [Indexed: 02/12/2024] Open
Abstract
Adenoid cystic carcinoma (ACC) is a rare neoplasm known for its indolent clinical course, risk of perineural invasion, and late onset of distant metastasis. Due to the scarcity of samples and the tumor's rarity, progress in developing effective treatments has been historically limited. To tackle this issue, a high-throughput screening of epigenetic drugs was conducted to identify compounds capable of disrupting the invasive properties of the tumor and its cancer stem cells (CSCs). ACC cells were screened for changes in tumor viability, chromatin decondensation, Snail inhibition along tumor migration, and disruption of cancer stem cells. Seven compounds showed potential clinical interest, and further validation showed that Scriptaid emerged as a promising candidate for treating ACC invasion. Scriptaid demonstrated a favorable cellular toxicity index, effectively inhibited Snail expression, induced hyperacetylation of histone, reduced cell migration, and effectively disrupted tumorspheres. Additionally, LMK235 displayed encouraging results in four out of five validation assays, further highlighting its potential in combating tumor invasion in ACC. By targeting the invasive properties of the tumor and CSCs, Scriptaid and LMK235 hold promise as potential treatments for ACC, with the potential to improve patient outcomes and pave the way for further research in this critical area.
Collapse
Affiliation(s)
- Paulo S. S. Pina
- Laboratory of Epithelial Biology, Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI 48109, USA; (P.S.S.P.); (Y.J.); (C.E.); (J.F.S.); (C.H.S.)
- Department of Stomatology, School of Dentistry, University of São Paulo, Sao Paulo 05508-270, Brazil;
| | - Yeejin Jang
- Laboratory of Epithelial Biology, Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI 48109, USA; (P.S.S.P.); (Y.J.); (C.E.); (J.F.S.); (C.H.S.)
| | - Carolina Emerick
- Laboratory of Epithelial Biology, Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI 48109, USA; (P.S.S.P.); (Y.J.); (C.E.); (J.F.S.); (C.H.S.)
- Oral Diagnosis Department, Piracicaba School of Dentistry, State University of Campinas, Piracicaba 13414-903, Brazil
| | - João Figueira Scarini
- Laboratory of Epithelial Biology, Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI 48109, USA; (P.S.S.P.); (Y.J.); (C.E.); (J.F.S.); (C.H.S.)
- Oral Diagnosis Department, Piracicaba School of Dentistry, State University of Campinas, Piracicaba 13414-903, Brazil
| | - Suzana C. O. M. Sousa
- Department of Stomatology, School of Dentistry, University of São Paulo, Sao Paulo 05508-270, Brazil;
| | - Cristiane H. Squarize
- Laboratory of Epithelial Biology, Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI 48109, USA; (P.S.S.P.); (Y.J.); (C.E.); (J.F.S.); (C.H.S.)
- Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
| | - Rogerio M. Castilho
- Laboratory of Epithelial Biology, Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI 48109, USA; (P.S.S.P.); (Y.J.); (C.E.); (J.F.S.); (C.H.S.)
- Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
| |
Collapse
|
2
|
Cicirò Y, Ragusa D, Nevado PT, Lattanzio R, Sala G, DesRochers T, Millard M, Andersson MK, Stenman G, Sala A. The mitotic checkpoint kinase BUB1 is a direct and actionable target of MYB in adenoid cystic carcinoma. FEBS Lett 2024; 598:252-265. [PMID: 38112379 DOI: 10.1002/1873-3468.14786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Revised: 10/16/2023] [Accepted: 11/08/2023] [Indexed: 12/21/2023]
Abstract
Adenoid cystic carcinoma (ACC) is a head and neck cancer that frequently originates in salivary glands, but can also strike other exocrine glands such as the breast. A key molecular alteration found in the majority of ACC cases is MYB gene rearrangements, leading to activation of the oncogenic transcription factor MYB. In this study, we used immortalised breast epithelial cells and an inducible MYB transgene as a model of ACC. Molecular profiling confirmed that MYB-driven gene expression causes a transition into an ACC-like state. Using this new cell model, we identified BUB1 as a targetable kinase directly controlled by MYB, whose pharmacological inhibition caused MYB-dependent synthetic lethality, growth arrest and apoptosis of patient-derived cells and organoids.
Collapse
Affiliation(s)
- Ylenia Cicirò
- Department of Life Sciences, Centre for Inflammation Research and Molecular Medicine (CIRTM), Brunel University London, Uxbridge, UK
| | - Denise Ragusa
- Department of Life Sciences, Centre for Genomic Engineering and Maintenance (CenGEM), Brunel University London, Uxbridge, UK
| | - Paloma Tejera Nevado
- Sahlgrenska Center for Cancer Research Department of Pathology, University of Gothenburg, Sweden
| | - Rossano Lattanzio
- Center for Advanced Studies and Technology (CAST); Department of Innovative Technologies in Medicine & Dentistry, University of Chieti-Pescara, Italy
| | - Gianluca Sala
- Center for Advanced Studies and Technology (CAST); Department of Innovative Technologies in Medicine & Dentistry, University of Chieti-Pescara, Italy
| | | | | | - Mattias K Andersson
- Sahlgrenska Center for Cancer Research Department of Pathology, University of Gothenburg, Sweden
| | - Göran Stenman
- Sahlgrenska Center for Cancer Research Department of Pathology, University of Gothenburg, Sweden
| | - Arturo Sala
- Department of Life Sciences, Centre for Inflammation Research and Molecular Medicine (CIRTM), Brunel University London, Uxbridge, UK
| |
Collapse
|
3
|
Viragova S, Aparicio L, Palmerini P, Zhao J, Valencia Salazar LE, Schurer A, Dhuri A, Sahoo D, Moskaluk CA, Rabadan R, Dalerba P. Inverse agonists of retinoic acid receptor/retinoid X receptor signaling as lineage-specific antitumor agents against human adenoid cystic carcinoma. J Natl Cancer Inst 2023; 115:838-852. [PMID: 37040084 PMCID: PMC10323906 DOI: 10.1093/jnci/djad062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2022] [Revised: 03/13/2023] [Accepted: 04/02/2023] [Indexed: 04/12/2023] Open
Abstract
BACKGROUND Adenoid cystic carcinoma (ACC) is a lethal malignancy of exocrine glands, characterized by the coexistence within tumor tissues of 2 distinct populations of cancer cells, phenotypically similar to the myoepithelial and ductal lineages of normal salivary epithelia. The developmental relationship linking these 2 cell types, and their differential vulnerability to antitumor treatments, remains unknown. METHODS Using single-cell RNA sequencing, we identified cell-surface markers (CD49f, KIT) that enabled the differential purification of myoepithelial-like (CD49fhigh/KITneg) and ductal-like (CD49flow/KIT+) cells from patient-derived xenografts (PDXs) of human ACCs. Using prospective xenotransplantation experiments, we compared the tumor-initiating capacity of the 2 cell types and tested whether one could differentiate into the other. Finally, we searched for signaling pathways with differential activation between the 2 cell types and tested their role as lineage-specific therapeutic targets. RESULTS Myoepithelial-like cells displayed higher tumorigenicity than ductal-like cells and acted as their progenitors. Myoepithelial-like and ductal-like cells displayed differential expression of genes encoding for suppressors and activators of retinoic acid signaling, respectively. Agonists of retinoic acid receptor (RAR) or retinoid X receptor (RXR) signaling (all-trans retinoic acid, bexarotene) promoted myoepithelial-to-ductal differentiation, whereas suppression of RAR/RXR signaling with a dominant-negative RAR construct abrogated it. Inverse agonists of RAR/RXR signaling (BMS493, AGN193109) displayed selective toxicity against ductal-like cells and in vivo antitumor activity against PDX models of human ACC. CONCLUSIONS In human ACCs, myoepithelial-like cells act as progenitors of ductal-like cells, and myoepithelial-to-ductal differentiation is promoted by RAR/RXR signaling. Suppression of RAR/RXR signaling is lethal to ductal-like cells and represents a new therapeutic approach against human ACCs.
Collapse
Affiliation(s)
- Sara Viragova
- Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA
- Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA
- Columbia Stem Cell Initiative, Columbia University Medical Center, New York, NY, USA
- Integrated Program in Cellular, Molecular and Biomedical Studies, Columbia University, New York, NY, USA
| | - Luis Aparicio
- Program for Mathematical Genomics, Department of Systems Biology, Columbia University, New York, NY, USA
- Department of Biomedical Informatics, Columbia University, New York, NY, USA
| | - Pierangela Palmerini
- Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA
- Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA
- Columbia Stem Cell Initiative, Columbia University Medical Center, New York, NY, USA
| | - Junfei Zhao
- Program for Mathematical Genomics, Department of Systems Biology, Columbia University, New York, NY, USA
- Department of Biomedical Informatics, Columbia University, New York, NY, USA
| | - Luis E Valencia Salazar
- Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA
- Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA
- Columbia Stem Cell Initiative, Columbia University Medical Center, New York, NY, USA
| | - Alexandra Schurer
- Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA
- Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA
| | - Anika Dhuri
- Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA
| | - Debashis Sahoo
- Department of Pediatrics, University of California San Diego, San Diego, CA, USA
- Department of Computer Science and Engineering, University of California San Diego, San Diego, CA, USA
- Rebecca and John Moores Comprehensive Cancer Center, University of California San Diego, San Diego, CA, USA
| | - Christopher A Moskaluk
- Department of Pathology, University of Virginia School of Medicine, Charlottesville, VA, USA
| | - Raul Rabadan
- Program for Mathematical Genomics, Department of Systems Biology, Columbia University, New York, NY, USA
- Department of Biomedical Informatics, Columbia University, New York, NY, USA
| | - Piero Dalerba
- Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA
- Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA
- Columbia Stem Cell Initiative, Columbia University Medical Center, New York, NY, USA
- Department of Medicine, Columbia University Medical Center, New York, NY, USA
- Digestive and Liver Disease Research Center, Columbia University Medical Center, New York, NY, USA
| |
Collapse
|
4
|
Lee DY, Brayer KJ, Mitani Y, Burns EA, Rao PH, Bell D, Williams MD, Ferrarotto R, Pytynia KB, El-Naggar AK, Ness SA. Oncogenic Orphan Nuclear Receptor NR4A3 Interacts and Cooperates with MYB in Acinic Cell Carcinoma. Cancers (Basel) 2020; 12:E2433. [PMID: 32867110 PMCID: PMC7565926 DOI: 10.3390/cancers12092433] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Accepted: 08/24/2020] [Indexed: 12/23/2022] Open
Abstract
Acinic cell carcinoma (AcCC) is a morphologically distinctive salivary gland malignancy often associated with chromosome rearrangements leading to overexpression of the NR4A3 transcription factor. However, little is known about how NR4A3 contributes to AcCC biology. Detailed RNA-sequencing of 21 archived AcCC samples revealed fusion reads arising from recurrent t(4;9), t(9;12), t(8;9) or t(2;4) chromosomal translocations, which positioned highly active enhancers adjacent to the promoter of the NR4A3 gene or the closely related NR4A2 gene, resulting in their aberrant overexpression. Transcriptome analyses revealed several distinct subgroups of AcCC tumors, including a subgroup that overexpressed both NR4A3 and MSANTD3. A poor survival subset of the tumors with high-grade transformation expressed NR4A3 and POMC as well as MYB, an oncogene that is the major driver in a different type of salivary gland tumor, adenoid cystic carcinoma. The combination of NR4A3 and MYB showed cooperativity in regulating a distinct set of genes. In addition, the ligand binding domain of NR4A3 directly bound the Myb DNA binding domain. Transformation assays indicated that, while overexpressed NR4A3 was sufficient to generate transformed colonies, the combination of NR4A3 plus Myb was more potent, leading to anchorage-independent growth and increased cellular invasiveness. The results confirm that NR4A3 and NR4A2 are the main driver genes of AcCC and suggest that concurrent overexpression of NR4A3 and MYB defines a subset of AcCC patients with high-grade transformation that display exceptionally poor outcome.
Collapse
Affiliation(s)
- David Y. Lee
- Department of Internal Medicine, Division of Hematology/Oncology, Section of Radiation Oncology, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA; (D.Y.L.); (E.A.B.)
| | - Kathryn J. Brayer
- Department of Internal Medicine, Division of Molecular Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA;
| | - Yoshitsugu Mitani
- Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; (Y.M.); (D.B.); (M.D.W.)
| | - Eric A. Burns
- Department of Internal Medicine, Division of Hematology/Oncology, Section of Radiation Oncology, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA; (D.Y.L.); (E.A.B.)
| | - Pulivarthi H. Rao
- Department of Pediatrics, Texas Children’s Cancer and Hematology Center, Texas Children’s Hospital, Baylor College of Medicine, Houston, TX 77030, USA;
| | - Diana Bell
- Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; (Y.M.); (D.B.); (M.D.W.)
| | - Michelle D. Williams
- Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; (Y.M.); (D.B.); (M.D.W.)
| | - Renata Ferrarotto
- Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA;
| | - Kristen B. Pytynia
- Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA;
| | - Adel K. El-Naggar
- Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; (Y.M.); (D.B.); (M.D.W.)
| | - Scott A. Ness
- Department of Internal Medicine, Division of Molecular Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA;
- Comprehensive Cancer Center, University of New Mexico, Albuquerque, NM 87131, USA
| |
Collapse
|
5
|
Ju YS, Alexandrov LB, Gerstung M, Martincorena I, Nik-Zainal S, Ramakrishna M, Davies HR, Papaemmanuil E, Gundem G, Shlien A, Bolli N, Behjati S, Tarpey PS, Nangalia J, Massie CE, Butler AP, Teague JW, Vassiliou GS, Green AR, Du MQ, Unnikrishnan A, Pimanda JE, Teh BT, Munshi N, Greaves M, Vyas P, El-Naggar AK, Santarius T, Collins VP, Grundy R, Taylor JA, Hayes DN, Malkin D, Foster CS, Warren AY, Whitaker HC, Brewer D, Eeles R, Cooper C, Neal D, Visakorpi T, Isaacs WB, Bova GS, Flanagan AM, Futreal PA, Lynch AG, Chinnery PF, McDermott U, Stratton MR, Campbell PJ. Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. eLife 2014; 3:e02935. [PMID: 25271376 PMCID: PMC4371858 DOI: 10.7554/elife.02935] [Citation(s) in RCA: 270] [Impact Index Per Article: 27.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2014] [Accepted: 09/26/2014] [Indexed: 01/04/2023] Open
Abstract
Recent sequencing studies have extensively explored the somatic alterations present in the nuclear genomes of cancers. Although mitochondria control energy metabolism and apoptosis, the origins and impact of cancer-associated mutations in mtDNA are unclear. In this study, we analyzed somatic alterations in mtDNA from 1675 tumors. We identified 1907 somatic substitutions, which exhibited dramatic replicative strand bias, predominantly C > T and A > G on the mitochondrial heavy strand. This strand-asymmetric signature differs from those found in nuclear cancer genomes but matches the inferred germline process shaping primate mtDNA sequence content. A number of mtDNA mutations showed considerable heterogeneity across tumor types. Missense mutations were selectively neutral and often gradually drifted towards homoplasmy over time. In contrast, mutations resulting in protein truncation undergo negative selection and were almost exclusively heteroplasmic. Our findings indicate that the endogenous mutational mechanism has far greater impact than any other external mutagens in mitochondria and is fundamentally linked to mtDNA replication.
Collapse
Affiliation(s)
- Young Seok Ju
- Cancer Genome Project,
Wellcome Trust Sanger Institute,
Hinxton, United Kingdom
| | - Ludmil B Alexandrov
- Cancer Genome Project,
Wellcome Trust Sanger Institute,
Hinxton, United Kingdom
| | - Moritz Gerstung
- Cancer Genome Project,
Wellcome Trust Sanger Institute,
Hinxton, United Kingdom
| | - Inigo Martincorena
- Cancer Genome Project,
Wellcome Trust Sanger Institute,
Hinxton, United Kingdom
| | - Serena Nik-Zainal
- Cancer Genome Project,
Wellcome Trust Sanger Institute,
Hinxton, United Kingdom
| | - Manasa Ramakrishna
- Cancer Genome Project,
Wellcome Trust Sanger Institute,
Hinxton, United Kingdom
| | - Helen R Davies
- Cancer Genome Project,
Wellcome Trust Sanger Institute,
Hinxton, United Kingdom
| | - Elli Papaemmanuil
- Cancer Genome Project,
Wellcome Trust Sanger Institute,
Hinxton, United Kingdom
| | - Gunes Gundem
- Cancer Genome Project,
Wellcome Trust Sanger Institute,
Hinxton, United Kingdom
| | - Adam Shlien
- Cancer Genome Project,
Wellcome Trust Sanger Institute,
Hinxton, United Kingdom
| | - Niccolo Bolli
- Cancer Genome Project,
Wellcome Trust Sanger Institute,
Hinxton, United Kingdom
| | - Sam Behjati
- Cancer Genome Project,
Wellcome Trust Sanger Institute,
Hinxton, United Kingdom
| | - Patrick S Tarpey
- Cancer Genome Project,
Wellcome Trust Sanger Institute,
Hinxton, United Kingdom
| | - Jyoti Nangalia
- Cancer Genome Project,
Wellcome Trust Sanger Institute,
Hinxton, United Kingdom
- Cambridge University Hospitals NHS Foundation
Trust, Cambridge, United Kingdom
- Department of Haematology,
University of Cambridge, Cambridge, United
Kingdom
| | - Charles E Massie
- Cancer Genome Project,
Wellcome Trust Sanger Institute,
Hinxton, United Kingdom
- Cambridge University Hospitals NHS Foundation
Trust, Cambridge, United Kingdom
- Department of Haematology,
University of Cambridge, Cambridge, United
Kingdom
| | - Adam P Butler
- Cancer Genome Project,
Wellcome Trust Sanger Institute,
Hinxton, United Kingdom
| | - Jon W Teague
- Cancer Genome Project,
Wellcome Trust Sanger Institute,
Hinxton, United Kingdom
| | - George S Vassiliou
- Cancer Genome Project,
Wellcome Trust Sanger Institute,
Hinxton, United Kingdom
- Cambridge University Hospitals NHS Foundation
Trust, Cambridge, United Kingdom
- Department of Haematology,
University of Cambridge, Cambridge, United
Kingdom
| | - Anthony R Green
- Cambridge University Hospitals NHS Foundation
Trust, Cambridge, United Kingdom
- Department of Haematology,
University of Cambridge, Cambridge, United
Kingdom
| | - Ming-Qing Du
- Cambridge University Hospitals NHS Foundation
Trust, Cambridge, United Kingdom
| | - Ashwin Unnikrishnan
- Lowy Cancer Research
Centre, University of New South Wales,
Sydney, Australia
| | - John E Pimanda
- Lowy Cancer Research
Centre, University of New South Wales,
Sydney, Australia
| | - Bin Tean Teh
- Laboratory of Cancer
Epigenome, National Cancer Centre,
Singapore, Singapore
- Duke-NUS Graduate Medical School,
Singapore, Singapore
| | - Nikhil Munshi
- Department of Hematologic
Oncology, Dana-Farber Cancer Institute,
Boston, United States
| | - Mel Greaves
- Institute of Cancer Research, Sutton,
London, United Kingdom
| | - Paresh Vyas
- Weatherall Institute for Molecular
Medicine, University of Oxford,
Oxford, United Kingdom
| | - Adel K El-Naggar
- Department of Pathology,
MD Anderson Cancer Center, Houston, United
States
| | - Tom Santarius
- Cambridge University Hospitals NHS Foundation
Trust, Cambridge, United Kingdom
| | - V Peter Collins
- Cambridge University Hospitals NHS Foundation
Trust, Cambridge, United Kingdom
| | - Richard Grundy
- Children's Brain Tumour Research
Centre, University of Nottingham,
Nottingham, United Kingdom
| | - Jack A Taylor
- National Institute of Environmental
Health Sciences, National Institute of
Health, Triangle,
North Carolina, United
States
| | - D Neil Hayes
- Department of Internal
Medicine, University of North Carolina,
Chapel
Hill, United States
| | - David Malkin
- Hospital for Sick
Children, University of Toronto,
Toronto, Canada
| | - Christopher S Foster
- Department of Molecular and Clinical
Cancer Medicine, University of Liverpool,
London, United Kingdom
- HCA Pathology Laboratories,
London, United Kingdom
| | - Anne Y Warren
- Cambridge University Hospitals NHS Foundation
Trust, Cambridge, United Kingdom
| | - Hayley C Whitaker
- Cancer Research UK Cambridge
Institute, University of Cambridge,
Cambridge, United Kingdom
| | - Daniel Brewer
- Institute of Cancer Research, Sutton,
London, United Kingdom
- School of Biological
Sciences, University of East Anglia,
Norwich, United Kingdom
| | - Rosalind Eeles
- Institute of Cancer Research, Sutton,
London, United Kingdom
| | - Colin Cooper
- Institute of Cancer Research, Sutton,
London, United Kingdom
- School of Biological
Sciences, University of East Anglia,
Norwich, United Kingdom
| | - David Neal
- Cancer Research UK Cambridge
Institute, University of Cambridge,
Cambridge, United Kingdom
| | - Tapio Visakorpi
- Institute of Biosciences and Medical
Technology - BioMediTech and Fimlab Laboratories,
University of Tampere and Tampere University Hospital,
Tampere, Finland
| | - William B Isaacs
- Department of Oncology,
Johns Hopkins University, Baltimore, United
States
| | - G Steven Bova
- Institute of Biosciences and Medical
Technology - BioMediTech and Fimlab Laboratories,
University of Tampere and Tampere University Hospital,
Tampere, Finland
| | - Adrienne M Flanagan
- Department of
Histopathology, Royal National Orthopaedic
Hospital, Middlesex, United Kingdom
- University College London Cancer
Institute, University College London,
London, United Kingdom
| | - P Andrew Futreal
- Cancer Genome Project,
Wellcome Trust Sanger Institute,
Hinxton, United Kingdom
- Department of Genomic
Medicine, The University of Texas, MD Anderson Cancer
Center, Houston, Texas, United States
| | - Andy G Lynch
- Cancer Research UK Cambridge
Institute, University of Cambridge,
Cambridge, United Kingdom
| | - Patrick F Chinnery
- Wellcome Trust Centre for Mitochondrial
Research, Institute of Genetic Medicine, Newcastle
University, Newcastle-upon-tyne, United
Kingdom
| | - Ultan McDermott
- Cancer Genome Project,
Wellcome Trust Sanger Institute,
Hinxton, United Kingdom
- Cambridge University Hospitals NHS Foundation
Trust, Cambridge, United Kingdom
| | - Michael R Stratton
- Cancer Genome Project,
Wellcome Trust Sanger Institute,
Hinxton, United Kingdom
| | - Peter J Campbell
- Cancer Genome Project,
Wellcome Trust Sanger Institute,
Hinxton, United Kingdom
- Cambridge University Hospitals NHS Foundation
Trust, Cambridge, United Kingdom
- Department of Haematology,
University of Cambridge, Cambridge, United
Kingdom
| |
Collapse
|